Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07151820 · ClinicalTrials.gov registry record
A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients
A clinical trial of Leukemia, Chronic Myeloid, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 2,546
- Enrollment target
- 1
- Study location
NCT07151820: Completed study of Leukemia, Chronic Myeloid, sponsored by Novartis Pharmaceuticals.
NCT07151820 is a study of Leukemia, Chronic Myeloid that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,546 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07151820, a study of Leukemia, Chronic Myeloid, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 2,546 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study was to assess the frequency of adverse events (AEs) experienced by chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) and evaluate their impact on treatment adjustments as well as the burden of AEs on healthcare resource use (HRU) and costs. This study used real-world administrative claims data from the PharMetrics Plus database. AEs of interest were selected based on information obtained from the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, Chronic Myeloid Leukemia Version 1. 2024 and clinical inputs. Given the nature of claims data, only AEs of interest that required medical attention (i.e., resulted in a claim record) were captured in this study.
Primary Outcome
The Study Period spanned from treatment initiation until treatment discontinuation, one day before treatment switch to another CML treatment, end of data availability, end of health plan coverage, or death, whichever came first.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,546 participants |
| Start Date | 2024-04-08 |
| Est. Completion | 2024-10-22 |
What the finished NCT07151820 record still lists
NCT07151820 is an observational study that tracks outcomes without assigning an intervention. Its 2,546 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Leukemia, Chronic Myeloid appearing as the primary indexed condition, and to 0 interventions.
NCT07151820 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT07151820 about?
NCT07151820 is a clinical study titled "A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients". The aim of this study was to assess the frequency of adverse events (AEs) experienced by chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) and evaluate their impact on treatment adjustments as well as the burden of AEs on healthcare resource use (HRU) and costs. ...
What is the current status of trial NCT07151820?
This trial is currently completed. The enrollment target is 2,546 participants. The study started on 2024-04-08. Estimated completion is 2024-10-22.
What conditions does trial NCT07151820 study?
This clinical trial studies the following conditions: Leukemia, Chronic Myeloid.
Who is sponsoring clinical trial NCT07151820?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07151820 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Chronic Myeloid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05931276 · 2,540 participants · Phase 3
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
- NCT00018057 · 2,530 participants · Phase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- NCT04142177 · 2,529 participants · NA
Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response
- NCT06018285 · 2,572 participants · NA
Stepped Approach to Reducing Risk of Suicide in Primary Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI